Aethlon Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
76.5%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$3.23next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Second Quarter Fiscal 2027 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Australian Oncology Trial Cohort Enrollment Quarterly3.0Target: Cohort 3 completion (3 patients treated)
Cash and Cash Equivalents Quarterly5MTarget: Sufficient capital to fund operations beyond 12 months
Annual Operating Expenses Annually7.3MTarget: Continued cost containment and operational efficiency
Watch Items
- Going Concern QualificationTrigger: Inability to secure additional equity or strategic financing within 12 monthsAction: Accelerate ATM program sales, seek strategic partnerships, or explore alternative financing structures
- Australian Oncology Trial Cohort 3 Safety ReadoutTrigger: Occurrence of any serious adverse events (SAEs) or dose-limiting toxicities (DLTs)Action: Convene independent Data Safety Monitoring Board (DSMB) to review safety data and determine trial progression
- Nasdaq Listing ComplianceTrigger: Failure to maintain minimum bid price or stockholders' equity requirementsAction: Implement reverse stock split or execute capital raises to restore compliance
Research as of 20 Jun 2026